Researchers have discovered a potential neuroimaging biomarker that could help personalize treatments for depression.
McGill researchers have identified a small region in the genome that conclusively plays a role in the development of psychiatric disease and obesity.
Lithium is a ‘gold standard’ drug for treating bipolar disorder, however not everyone responds in the same way. New research published in BioMed Central’s open access journal Biology of Mood & Anxiety Disorders finds that this is true at the levels of gene activation, especially in the activation or repression of genes which alter the level the apoptosis (programmed cell death).
The same gene variations that make it difficult to stop smoking also increase the likelihood that heavy smokers will respond to nicotine-replacement therapy and drugs that thwart cravings, a new study shows.
Researchers believe they have identified key genes associated with schizophrenia and propose a prototype predictive test.
These findings are not about the classic story of gift-giving, although the MAGI genes (officially named membrane associated guanylate kinase, WW and PDZ domain containing proteins) do influence brain function in important ways.
Antidepressive drugs reduce the mortality rate of schizophrenic patients, while treatment with bensodiazepines greatly increases it, especially as regards suicide. Giving several antipsychotics simultaneously, however, seems to have no effect at all. This according to a new study examining different drug combinations administered to patients with schizophrenia.
A breakthrough blood test which identifies depression and its specific subtypes in teens has been developed by a scientist at Northwestern University. Scientist were able to distinguish 11 specific genetic markers apparent within teens with depression and those without depression. Additionally, 18 out of 26 genetic markers previously identified, distinguished between teens who suffered major depression alone and those whose depression was coupled with anxiety disorders. This research is promising as, not only can depression and its subtypes be diagnosed through a simple blood test, but also gives hope for the development of individualized treatment options.
Depression is common enough, afflicting one in ten adults in the United States. It seems the possibility of depression must be “hard-wired” into our brains. This has led biologists to propose several theories to account for how depression, or behaviors linked to it, can somehow offer an evolutionary advantage.
New research published today in Archives of General Psychiatry suggests antidepressants such as Prozac (fluoxetine) neither increase or decrease suicidality in children. However, they are effective medications to control and reduce suicidal behavior in adults.